Table 2.
Clinical characteristics of NCT and CT group patients
| Characteristics | NCT, % (76; 65.5%) | CT, % (40; 34.5%) | p value |
|---|---|---|---|
| Median age, years | 58 | 54 | 0.604 |
| DFI, n (%) | 0.603 | ||
| ≤24 months | 23 (30.3) | 14 (35.0) | |
| >24 months | 53 (69.7) | 26 (65.0) | |
| ER, n (%) | 0.701 | ||
| Negative | 6 (7.9) | 4 (10.0) | |
| Positive | 70 (92.1) | 36 (90.0) | |
| PR, n (%) | 0.344 | ||
| Negative | 17 (22.4) | 6 (15.0) | |
| Positive | 59 (77.6) | 34 (85.0) | |
| HER2, n (%) | 0.112 | ||
| Negative | 62 (81.6) | 31 (77.5) | |
| Positive | 5 (6.58) | 7 (17.5) | |
| Unknown | 9 (11.8) | 2 (5.0) | |
| Histological grade, n (%) | 0.359 | ||
| I | 4 (5.3) | 3 (7.5) | |
| II | 41 (53.9) | 26 (65.0) | |
| III | 31 (40.8) | 11 (27.5) | |
| Stage, n (%) | 0.041 | ||
| I | 16 (21.5) | 2 (5.0) | |
| II | 30 (32.9) | 13 (32.5) | |
| III | 28 (40.8) | 17 (42.5) | |
| IV | 2 (3.9) | 8 (5.0) | |
| Metastatic sites, n (%) | 0.312 | ||
| Lymph nodes | 11 (14.5) | 12 (30.0) | |
| Bone | 39 (51.3) | 23 (57.5) | |
| Visceral | 35 (46.1) | 18 (45.0) | |
| Number of metastatic sites, n (%) | 0.022 | ||
| 1 | 56 (73.7) | 21 (52.5) | |
| ≥2 | 20 (26.3) | 19 (47.5) | |
| DFS, months, n (%) | |||
| ≤24 | 23 (30.3) | 14 (35.0) | 0.677 |
| >24 | 53 (69.7) | 26 (65.0) |
DFI, disease-free interval.